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Abstract
Background: Age of onset of multimorbidity and its prevalence are well documented.
However, its contribution to inequalities in life expectancy has yet to be quantified.
Methods: A cohort of 1.1 million English people aged 45 and older were followed up
from 2001 to 2010. Multimorbidity was defined as having 2 or more of 30 major chronic
diseases. Multi-state models were used to estimate years spent healthy and with multi-
morbidity, stratified by sex, smoking status and quintiles of small-area deprivation.
Results: Unequal rates of multimorbidity onset and subsequent survival contributed to
higher life expectancy at age 65 for the least (Q1) compared with most (Q5) deprived:
there was a 2-year gap in healthy life expectancy for men [Q1: 7.7 years (95% confidence
interval: 6.4–8.5) vs Q5: 5.4 (4.4–6.0)] and a 3-year gap for women [Q1: 8.6 (7.5–9.4) vs Q5:
5.9 (4.8–6.4)]; a 1-year gap in life expectancy with multimorbidity for men [Q1: 10.4
(9.9–11.2) vs Q5: 9.1 (8.7–9.6)] but none for women [Q1: 11.6 (11.1–12.4) vs Q5: 11.5
(11.1–12.2)]. Inequalities were attenuated but not fully attributable to socio-economic dif-
ferences in smoking prevalence: multimorbidity onset was latest for never smokers and
subsequent survival was longer for never and ex smokers.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1340
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Original article
Conclusions: The association between social disadvantage and multimorbidity is com-
plex. By quantifying socio-demographic and smoking-related contributions to multimor-
bidity onset and subsequent survival, we provide evidence for more equitable allocation
of prevention and health-care resources to meet local needs.
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Introduction
Life expectancy at age 65 in the most deprived fifth of the
English population was 4 years shorter than in the least de-
prived fifth in 2010.1,2 The inverse gradient between mortal-
ity and socio-economic position is well established;
furthermore, deprivation affects age of multimorbidity onset
and number of concurrent medical conditions.3 However, it
is uncertain how disease patterns and multimorbidity influ-
ence mortality: do disadvantaged groups acquire diseases
more quickly and/or do they die earlier after becoming mul-
timorbid? It also remains unclear how much risk factors
such as smoking contribute to the inequality gaps in the
years lived with and without multimorbity or whether the
effects vary by sex. This is particularly relevant in ageing
populations, given the trend of widening inequalities in rela-
tive mortality across several high-income countries.4
The prevalence of multimorbidity increases rapidly with
age,3,5–7 with multimorbidity being the norm rather than
exception at very advanced ages.5,8 Estimates vary across
studies,5,9 ranging from 55 to 98% for populations aged
60 or older, due in part to differences in the definition of
multimorbidity, study setting and data-collection meth-
ods.5 Across studies in high-income countries, prevalence
is consistently higher in more disadvantaged groups.5
Prevalence for individuals aged 30–34 in the most deprived
areas was similar to those aged 45–49 in the least deprived
areas in a Scottish study.3
Many aspects of individuals’ health trajectories remain
underexplored. The majority of previous studies of the as-
sociation between social inequality and mortality assess
rates of disease accumulation and subsequent mortality
separately instead of jointly. For example, a longitudinal
study characterized population subgroups with distinct dif-
ferences in rates of disease accumulation,10 whereas an-
other study that controlled for deprivation compared
baseline measures of multimorbidity for predicting mortal-
ity.11 Studies of survival with and without multimorbidity
generally report higher mortality in multimorbid individu-
als, and mortality rates are higher when multimorbidity is
defined as the co-occurrence of at least three diseases.12
It is also rare that studies of health expectancies analyse
disease accumulation trajectories in detail, across progres-
sively severe disease states.7 Previous studies focused on
progressive decline in index conditions, e.g. cognitive func-
tion13 and cardiovascular diseases,14 without controlling
for comorbidity. A recent study analysed these trajectories
to develop projections of health expectancies with and
without multimorbidity in an English population, but in-
cluded socio-economic status as a predictor rather than
reporting socio-economic differentials.7
This study quantifies socio-economic differences in age-
specific rates of multimorbidity onset and subsequent mor-
tality, in a cohort representative of the English popula-
tion.15,16 It also estimates socio-economic and health
Key Messages
• By integrating temporal differences in multimorbidity onset, disease accumulation and survival, we quantified socio-
economic and smoking-related differentials in life expectancy with and without multimorbidity at age 65.
• Compared with those living in the most deprived areas, the life expectancy advantage of the least deprived consisted
of two components: delayed onset of multimorbidity (by 2 years for men and 3 years for women); and longer subse-
quent survival with multimorbidity (by 1 year for men but none for women).
• These differences were attenuated but not fully attributable to differences in smoker prevalence by neighbourhood
deprivation. Giving up smoking appeared to have little impact on delaying the age of onset of multimorbidity com-
pared with smokers; but served to extend years lived with multimorbidity.
• Neighbourhood deprivation is powerfully associated with the onset and subsequent survival with multimorbidity, in-
dependently of age, sex and smoking status.
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behaviour differentials in years spent with one, two or at
least three diseases.
Methods
Data sources
The study analyses linked electronic health records from
1.1 million English people aged 45 and over, followed up
from 2001 to 2010. These individuals contribute data to
the CALIBER (Clinical research using LInked Bespoke
studies and Electronic health Records) programme15 that
links primary care [Clinical Practice Research Datalink
(CPRD)], hospital [Hospital Episode Statistics (HES)],
specialist disease registry (Myocardial Ischaemia
National Audit Project) and national administrative
(Office for National Statistics death registry and area
deprivation) datasets. Electronic phenotypes of cardio-
vascular and several non-cardiovascular chronic diseases
developed in previous studies were used (Supplementary
Appendix A and B, available as Supplementary data at
IJE online).17
Study population
This study has an open cohort design, with individuals be-
coming cohort members on the earliest date that they ful-
filled all inclusion criteria: (i) registered with a
participating primary-care practice that has agreed to data
linkage; (ii) registered with a practice categorized as ‘up-
to-standard’, based on CPRD data-quality criteria, for at
least 1 year prior to study entry; (iii) aged 45 and over on 1
January 2001 or who turned 45 between 1 January 2001
and 25 March 2010.
Eligible individuals entered the study irrespective of ini-
tial health status. Approximately half (49%) of the individu-
als entered the study on 1 January 2001 and the remainder
entered at a broadly constant rate in subsequent years. The
start date was chosen such that there were sufficient obser-
vations of transitions between health states in the follow-up
period, to investigate changes in health within a statistical
analysis. The study end date was 25 March 2010—the latest
date for which linked data were available when this study
commenced. Individuals were followed up to the earliest of:
death, deregistration from the practice, last data collection
for the individual’s practice or the study end date. The study
included all 225 practices contributing linked data to
CALIBER—approximately 40% of CPRD practices.15
The study protocol was approved by the UK Medicines
& Healthcare products Regulatory Agency and registered
on Clinicaltrials.gov (Identifier: NCT02609516). Further
details on the dataset, its representativeness and exclusion
criteria can be found in Supplementary Appendix A, avail-
able as Supplementary data at IJE online.
Defining multimorbidity
A chronic disease was defined as a ‘health problem that
requires ongoing management over a period of years or
decades’18 and which ‘cannot be cured but can be con-
trolled by medication or other therapies’.19 A systematic
literature review of the diseases included in multimorbid-
ity studies was conducted and we received expert advice
from primary-care clinicians and clinical epidemiologists
on disease selection and definition (Supplementary
Appendix B, available as Supplementary data at IJE on-
line). Individuals concurrently having any 2 or more of a
selected list of 30 major chronic diseases (Supplementary
Appendix B Table 1, available as Supplementary data at
IJE online), without any disease treated as an index or
dominant condition,20 were defined as multimorbid.
Diagnosis dates of in-scope diseases were used, as estimates
based on these are generally more relevant to clinicians,
health-system planning and resource allocation than latent
dates of disease onset. Those without any in-scope diseases
were labelled ‘healthy’, regardless of whether they had any
other diseases.
Cohort characteristics
The main unit of exposure for this study was the quintile
of the English Index of Multiple Deprivation (IMD)
2007. The IMD is a composite index, combining multiple
domains of relative deprivation calculated at small-area
level, and the 2007 version was closest to the midpoint of
the study period.21 Based on residential addresses within
small areas with an average population of 1500, eligible
individuals were assigned to nationally derived quintiles,
with the least deprived in quintile one (Q1) and most de-
prived in quintile five (Q5). The IMD has been a useful
proxy for individual-level deprivation in an older popula-
tion22 and there has been little change in the geographical
patterning of IMD quintiles at the small-area level for the
preceding 25 years.23
The population was stratified by sex, IMD quintile
and smoking status (never, ex and current) into 30 subpo-
pulations, prior to analysis. The most recent smoking sta-
tus recorded in primary care prior to the individual’s
entry into the study was used and, if unrecorded, was set
to missing. Of the 1.3 million eligible individuals, 168 505
(13.1%) with missing smoking status were excluded
(details in Supplementary Appendix A, available as
Supplementary data at IJE online), as methods to treat
missing values in the statistical model used have yet to be
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developed. Hence, 1.1 million individuals were included
in the study.
Statistical methods
Age-specific multimorbidity prevalence, incidence rates
and mortality rates were calculated using standard formu-
lae,24 by sex and IMD quintile (Supplementary Appendix
D, available as Supplementary data at IJE online). To en-
able the use of parametric survival models, we verified that
all transition rates changed exponentially with age
(Supplementary Appendix C, available as Supplementary
data at IJE online).
A prognostic multi-state survival model was used to ana-
lyse the non-recoverable disease progression of individuals
between five health states—healthy, one disease, two dis-
eases, at least three diseases and dead—over time. Separate
models with the same structure were fitted to each of the 30
subpopulations. The health states and allowable transitions
between states are shown in Figure 1, and further details on
the model specification and the R package ‘msm’25 used in
fitting these models are provided in Supplementary
Appendix C, available as Supplementary data at IJE online.
The R ‘ELECT’ function14 used the estimated transition
rates from the multi-state model to estimate total life ex-
pectancies and partitioned them into life expectancies in
each living state.
Since analyses were stratified by the risk factors (sex,
IMD quintile and smoking status) rather than included as
covariates, their effects on disease accumulation and mor-
tality rates were not constrained to be proportional. We
could therefore characterize state-specific life expectancies
by each risk factor in detail. Within each strata, there were
sufficient transitions of individuals between health states
during the study to populate the model (Supplementary
Table C1, available as Supplementary data at IJE online).
The state-specific life expectancies were estimated for
the full age range of 45 and above, but are reported for the
reference age of 65, in order to reflect patterns of disease
accumulation and survival at older ages. Since individuals
were generally healthy between ages 45 and 65 regardless
of deprivation and smoking status, the use of an older ref-
erence age unmasks differential effects of these risk factors
later in life.
The total life expectancies were validated against those
estimated via period life table methods applied to the
English population and the study cohort (Supplementary
Table E3, available as Supplementary data at IJE online).
Results
Of the 1.1 million individuals in the study, 12.7% died
during follow-up. At baseline, 47.5% were healthy, 28.3%
had one disease and 24.1% were multimorbid. Individuals
in the least deprived quintile (Q1) had a healthier baseline
profile than those in the most deprived (Q5), with 10.9%
more individuals who were healthy and 11.3% fewer indi-
viduals who were multimorbid (Table 1).
Multimorbidity prevalence, incidence rates and
mortality rates
There was a clear social gradient and gap in multimorbid-
ity prevalence between the least and most deprived quin-
tiles between ages 45 and 80 (Figure 2). At ages 65–69, the
gap in multimorbidity prevalence was 14.4% in men (Q1:
34.5%, Q5: 48.9%) and 16.7% in women (Q1: 34.1%,
Q5: 50.8%) (Figure 2 and Supplementary Table D1a,
available as Supplementary data at IJE online). The preva-
lences for Q1 men at ages 65–69 were comparable to those
for Q5 men approximately 10 years younger, and those for
Q1 women at ages 65–69 were comparable to Q5 women
approximately 15 years younger.
Age-specific multimorbidity incidence rates were higher
for Q5 compared with Q1 for all ages and both sexes
(Figure 3 and Supplementary Table D1b, available as
Supplementary data at IJE online). Mortality rates were on
average six times as high for those with multimorbidity as
those without multimorbidity, across ages and across dep-
rivation quintiles (Figure 4 and Supplementary Tables D1c
and d, available as Supplementary data at IJE online). All
incidence and mortality rates, by sex and deprivation, dis-
played a broadly exponential and increasing age trend
(Figures 3 and 4).
Higher incidence rates, coupled with higher mortality
rates with and without multimorbidity, imply that individu-
als in Q5 spent less time without multimorbidity than indi-
viduals in Q1. A multi-state model was required to quantify
average time spent with multimorbidity, taking into account
rates of entry to and exits from each health state.
Life expectancies
Total life expectancies at age 65 by IMD quintile ranged
from 18.1 years [95% confidence interval (CI): 17.5–18.4]
for the least deprived (Q1) to 14.5 years (13.9–14.7) for the
Figure 1. Structure of the multi-state model, with five health states
(boxes) and seven allowable transitions (arrows) between states.
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most deprived (Q5) in men (Table 2) and 20.3 years (19.9–
20.5) (Q1) to 17.4 years (17.0–17.6) (Q5) in women
(Table 3).
For each deprivation quintile, life expectancy was sepa-
rated into years spent healthy and with successively higher
counts of concurrent diseases (Tables 2 and 3). For men,
there was a 2.3-year gap in life expectancy without multi-
morbidity between Q1 and Q5 [Q1: 7.7 years (95% CI:
6.3–8.5) vs Q5: 5.4 years (4.3–6.0)], followed by a further
1.3-year gap in life expectancy with multimorbidity [Q1:
10.4 years (9.9–11.2) vs Q5: 9.1 years (8.7–9.7)]. Across
quintiles, there were gradients in life expectancy in each
state (Figure 5A and Supplementary Table E1, available as
Supplementary data at IJE online). For women, there was
a 2.7-year gap in life expectancy without multimorbidity
[Q1: 8.6 years (7.3–9.4) vs Q5: 5.9 years (4.8–6.4)], but no
additional gap in life expectancy with multimorbidity [Q1:
11.6 years (11.0–12.5) vs Q5: 11.5 years (11.1–12.2)].
Across quintiles, there were gradients in life expectancy
only prior to multimorbidity onset, as women survived for
approximately 11.6 years regardless of quintile after be-
coming multimorbid (Figure 6A and Supplementary Table
E2, available as Supplementary data at IJE online).
To investigate whether these patterns were attributable
to socio-economic differences in smoking status, Figures 5
and 6B–D each displays state-specific life expectancies
stratified by smoking status. For each sex, life expectancy
without multimorbidity was highest for never smokers and
similar for ex and current smokers. In contrast, life expec-
tancy with multimorbidity was similar for never and ex
smokers and lowest for current smokers. This pattern was
more marked for men than for women.
More generally, total life expectancies at age 65 were
highest for never smokers and lowest for current smokers
across ages (Tables 2 and 3). When split by smoking status,
the gap in life expectancies between Q1 and Q5 persisted
but narrowed slightly, from 3.6 (overall) to 2.9–3.3 years
for men and from 2.9 (overall) to 2.0–2.6 years for women.
We then focused on the middle quintile (Q3) to examine
life expectancies with and without multimorbidity by smok-
ing status for ages 65–90. We have used Q3 as an exemplar
because of the five population strata (by deprivation quin-
tile) and its life-expectancy and multimorbidity accumula-
tion patterns were closest to those for the overall England
population. Furthermore, smoking-status differentials were
broadly similar across all deprivation quintiles, for both
sexes (Figures 7 and 8), and were thus generalizable across
quintiles. For Q3 individuals aged 65, never smokers had
the highest total life expectancy [men: 17.8 years (95% CI:
16.8–18.3), women: 20.0 years (19.5–20.3)], whereas life
expectancy was lowest for current smokers [men: 13.4 years
(12.4–14.0), women: 15.0 years (14.1–15.6)] (Tables 2A
and 2B). Smoking-status differentials were decomposed into
two effects: never smokers spent more remaining years
Table 1. Socio-demographic and health profile of individuals aged 45 and over, by IMD 2007 quintile. England, CALIBER 2001–
10
All quintiles Q1 (least deprived) Q2 Q3 Q4 Q5 (most deprived)
Cohort population (n) 1 114 563 289 328 277 591 222 901 196 953 127 790
Deaths (n) 141 951 28 758 32 839 29 815 28 857 21 682
Person-years (millions) 6.34 1.70 1.60 1.27 1.08 0.68
Females (%) 53.4 52.9 53.4 53.6 54.0 53.1
Age at baseline, years
Mean (SD) 58.8 (13.0) 58.0 (12.6) 59.0 (12.9) 59.4 (13.1) 59.2 (13.2) 58.8 (13.1)
45–54 (%) 48.8 51.7 48.0 46.8 47.8 49.4
55–64 (%) 21.4 21.2 22.2 22.0 20.9 19.9
65–74 (%) 15.8 14.9 16.0 16.4 16.3 15.9
75–84 (%) 10.3 9.0 10.2 10.7 11.2 11.3
85þ (%) 3.7 3.3 3.7 4.0 3.9 3.4
Health status at baseline
Healthy (%) 47.5 51.8 49.0 46.7 44.4 40.9
1 disease (%) 28.3 28.3 28.2 28.5 28.5 27.8
2 diseases (%) 13.6 12.0 13.0 14.0 14.9 16.2
3þ diseases (%) 10.5 7.9 9.7 10.9 12.2 15.0
Smoking status at baseline
Never smoker (%) 62.0 69.2 64.8 61.3 56.1 50.3
Ex smoker (%) 21.8 20.1 21.7 22.4 22.7 22.9
Current smoker (%) 16.2 10.6 13.5 16.3 21.2 26.8
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Figure 2. Prevalence of multimorbidity for adults aged 45 and over, by deprivation quintile, 2001–10, England, in men (left) and women (right).
Figure 3. Incidence rates of multimorbidity for adults aged 45 and over, by deprivation quintile, 2001–10, England, in men (left) and women (right).
Figure 4. Mortality rates for multimorbid adults aged 45 and over, by deprivation quintile, 2001–10, England, in men (left) and women (right).
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without multimorbidity than ex and current smokers
(Figures 7B and 8B); and never and ex smokers spent equal
numbers of years with multimorbidity and more years than
current smokers (Figures 7C and 8C). This 5-year difference
between never and current smokers’ total life expectancies
was much larger than the overall Q3 sex differential of
2.5 years (Supplementary Tables E1 and E2, available as
Supplementary data at IJE online).
Discussion
This large, population-based study of inequalities in multi-
morbidity demonstrates that socially disadvantaged men
become multimorbid 2 years earlier and, after becoming
multimorbid, survive for 1 year less than advantaged men.
Whilst disadvantaged women become multimorbid 3 years
earlier than advantaged women, this does not lead to sur-
vival differences with multimorbidity. Thus, the lower life
expectancy of disadvantaged men is due to both earlier
multimorbidity onset and earlier death. Conversely, for
disadvantaged women, it is mainly due to earlier multimor-
bidity onset. The social gradient in both age of onset and
survival with multimorbidity were attenuated but not fully
attributable to socio-economic differences in smoking
prevalence: within each deprivation quintile, the onset of
multimorbidity was delayed for never smokers and subse-
quent survival was extended for never and ex smokers.
Giving up smoking appears to have little impact on multi-
morbidity onset but delays subsequent death, suggesting
that interventions to change some health behaviours may
be more effective earlier in life.
Sex differences in survival after multimorbidity onset may
be due to differences in disease combinations and their asso-
ciated fatality rates. The state definitions of this multimor-
bidity model can be modified to investigate inequalities in
the onset and progression of specific diseases.
This novel longitudinal, multi-stage and multiple-
outcome approach allows us to concurrently study rates of
disease accumulation and death, to derive life expectancies
with and without multimorbidity. Additionally, we can es-
timate socio-economic, demographic and health-behaviour
impacts on these quantities.
The large-scale CALIBER dataset is nationally representa-
tive.16,17 Linking longitudinal primary care and hospital
records, including dates of disease diagnoses and death, ena-
bles investigation of a broad range of chronic diseases and
disease trajectories of individuals over a long time period.
The incidence and mortality rates of multimorbidity reported
Table 2. Life expectancies for men with and without multimorbidity at age 65, by IMD 2007 quintile, smoking status and health
state
Years spent without
multimorbidity
(95% CI)
Years spent with
multimorbidity
(95% CI)
Total
(95% CI)
Time spent with
multimorbidity
(%)
Overall Q1 (least deprived) 7.7 (6.3, 8.5) 10.4 (9.9, 11.2) 18.1 (17.5, 18.4) 57
Q2 7.3 (6.0, 7.9) 10.0 (9.7, 10.8) 17.4 (16.8, 17.7) 58
Q3 6.9 (5.4, 7.6) 9.8 (9.4, 10.7) 16.7 (16.2, 17.0) 59
Q4 6.2 (5.2, 6.8) 9.5 (9.1, 10.1) 15.7 (15.2, 16.0) 61
Q5 (most deprived) 5.4 (4.3, 6.0) 9.1 (8.7, 9.7) 14.5 (13.9, 14.7) 63
Never smokers Q1 (least deprived) 8.6 (6.2, 9.5) 10.3 (9.7, 11.8) 18.9 (18.0, 19.3) 54
Q2 8.1 (5.9, 9.0) 10.1 (9.6, 11.5) 18.3 (17.5, 18.7) 55
Q3 7.8 (5.3, 8.7) 10.0 (9.4, 11.5) 17.8 (16.8, 18.3) 56
Q4 7.2 (5.2, 8.2) 9.8 (9.3, 11.1) 17.1 (16.3, 17.5) 58
Q5 (most deprived) 6.6 (3.4, 7.5) 9.4 (8.8, 11.2) 16.0 (14.8, 16.5) 59
Ex smokers Q1 (least deprived) 6.8 (4.0, 7.8) 11 (10.2, 12.7) 17.8 (16.7, 18.2) 62
Q2 6.5 (3.8, 7.5) 10.6 (10, 12.3) 17.1 (16.0, 17.6) 62
Q3 6.2 (3.3, 7.1) 10.5 (9.8, 12.1) 16.6 (15.4, 17.1) 63
Q4 5.6 (3.0, 6.5) 10.0 (9.5, 11.6) 15.7 (14.6, 16.1) 64
Q5 (most deprived) 4.9 (2.2, 5.8) 9.6 (9.1, 11.2) 14.6 (13.6, 15.1) 66
Current smokers Q1 (least deprived) 6.3 (3.2, 7.2) 8.6 (8, 10.3) 14.9 (13.1, 15.5) 58
Q2 5.9 (3.3, 6.8) 8.3 (7.8, 9.7) 14.3 (13.1, 14.8) 58
Q3 5.5 (3.4, 6.3) 7.9 (7.4, 9.1) 13.4 (12.4, 14.0) 59
Q4 4.9 (3.3, 5.6) 7.6 (7.1, 8.5) 12.6 (11.7, 12.9) 61
Q5 (most deprived) 4.2 (2.8, 4.8) 7.4 (7.0, 8.2) 11.6 (10.9, 12.0) 64
This table is based on figures in Supplementary Appendix E, available as Supplementary data at IJE online.
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in this study result in prevalences similar to those reported in
other studies,3,5,6 despite different disease definitions and se-
lection criteria. The exponential distribution of diseases and
deaths across ages fits the model specifications well
(Supplementary Appendix C, available as Supplementary
data at IJE online). The six-fold difference in multimorbid
and non-multimorbid mortality rates suggests that it is
pertinent to analyse deaths at each stage in the disease-accu-
mulation pathway separately (Figure 1) to more accurately
estimate the impact of multimorbidity on lifespan.
The main study limitations were, first, electronic health
records are designed to serve health services and cannot be
assumed to provide complete, accurate and standardized
measures of individuals’ health status.17 For example, diag-
nostic coding practices may vary between primary-care pro-
viders and over time. Although minimized through record
linkage, some diagnoses might be under-recorded, particu-
larly mental health and musculoskeletal disorders.3 Second,
standard and complete measures of disease severity, dura-
tion and interactions with acute diseases were not available.
Third, unlike survey data, routine health-care datasets only
record ecological measures of socio-economic status. We
used the best available composite index of small-area depri-
vation as a proxy measure of compositional and contextual
effects of social environments on individuals’ health.18,26
Many studies have shown that contextual measures have an
independent effect on health outcomes after taking into ac-
count individual risk factor profiles.27,28 Ideally, both indi-
vidual and area-based measures should be used together in
analysis. Accordingly, we have used smoking status as a
marker of individual health behaviour and small-area depri-
vation as a marker of the contextual effects of more up-
stream risks of the living environment (such as barriers to
access to services, unemployment and crime, which are in-
cluded in the composite index of area deprivation21).
Contextual effects may operate through several pathways,
including material or infrastructural resources, shared
norms and social cohesion.29
Smoking is a modifiable behaviour that could be affected
by disease onset. Smoking status changes in turn affect mul-
timorbidity onset and subsequent survival. In our study,
smoking status could not be incorporated as time-varying
due to inconsistencies in recording practices and uncertain-
ties in the timings of smoking-status changes. A validation
study found that, whilst current smokers are likely to be cor-
rectly identified, the recording of ex and never smokers was
inconsistent with prevalences from a national survey.30
Finally, we were unable to include other risk factors in
the model because of high levels of missing data
(Supplementary Table A1, available as Supplementary data
Table 3. Life expectancies for women with and without multimorbidity at age 65, by IMD 2007 quintile, smoking status and
health state
Years spent without
multimorbidity
(95% CI)
Years spent with
multimorbidity
(95% CI)
Total
(95% CI)
Time spent with
multimorbidity
(%)
Overall Q1 (least deprived) 8.6 (7.3, 9.4) 11.6 (11.0, 12.5) 20.3 (19.9, 20.5) 57
Q2 8.1 (7.0, 8.8) 11.8 (11.3, 12.5) 19.9 (19.5, 20.1) 59
Q3 7.6 (6.5, 8.3) 11.6 (11.1, 12.4) 19.2 (18.8, 19.5) 60
Q4 6.8 (5.9, 7.5) 11.7 (11.2, 12.3) 18.5 (18.2, 18.8) 63
Q5 (most deprived) 5.9 (4.8, 6.4) 11.5 (11.1, 12.2) 17.4 (17.0, 17.6) 66
Never smokers Q1 (least deprived) 9.2 (7.4, 10.1) 11.6 (11.0, 12.9) 20.9 (20.4, 21.2) 56
Q2 8.7 (7.4, 9.6) 11.8 (11.3, 12.7) 20.6 (20.0, 20.9) 58
Q3 8.3 (6.7, 9.2) 11.7 (11.1, 12.9) 20.0 (19.5, 20.3) 59
Q4 7.7 (6.0, 8.6) 12.0 (11.3, 13.2) 19.7 (19.2, 20.0) 61
Q5 (most deprived) 7.0 (4.9, 7.9) 12.0 (11.3, 13.3) 18.9 (18.2, 19.3) 63
Ex smokers Q1 (least deprived) 7.2 (3.4, 7.2) 12.0 (8.9, 11.6) 19.3 (18.2, 19.7) 63
Q2 6.8 (3.6, 6.8) 12.4 (9.2, 11.3) 19.2 (18.2, 19.7) 65
Q3 6.3 (3.4, 6.5) 12.3 (8.7, 10.8) 18.6 (17.6, 19.1) 66
Q4 5.6 (3.4, 5.8) 12.3 (8.5, 10.0) 18.0 (17.2, 18.5) 69
Q5 (most deprived) 4.8 (2.8, 4.7) 12.0 (8.8, 10.3) 16.7 (15.8, 17.1) 71
Current smokers Q1 (least deprived) 6.2 (4.0, 8.4) 9.8 (11.2, 14.3) 15.9 (14.8, 16.5) 61
Q2 5.9 (4.1, 7.9) 9.8 (11.6, 14.2) 15.7 (14.8, 16.2) 62
Q3 5.6 (3.5, 7.5) 9.4 (11.5, 14.2) 15.0 (14.1, 15.6) 63
Q4 5.1 (3.4, 6.7) 9.1 (11.6, 13.9) 14.1 (13.4, 14.5) 64
Q5 (most deprived) 4.0 (2.4, 5.6) 9.3 (11.3, 13.6) 13.3 (12.8, 13.7) 70
This table is based on figures in Supplementary Appendix E, available as Supplementary data at IJE online.
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at IJE online) and the potential for model over-specifica-
tion. However, health expectancies are presented in detail
by sex, deprivation quintile, smoking status, age and health
state, capturing the main drivers of socio-economic in-
equality in health outcomes.
The increasing burden of multimorbidity places strain
on the National Health Service (NHS), which is a tax-
funded, universal system. Our results provide compelling
evidence for resource allocation that better reflects the
needs of local populations. This should include not only
higher levels of health-care resources and targeted inter-
ventions for prevention, but also the recruitment of a
workforce with expertise in managing multimorbidity.
Supplementary data
Supplementary data are available at IJE online.
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